Results · Apr-Jun 2026 · filed 11 Aug 2026
Genpharmasec Q1 FY27 results
Sales grew 313% to ₹49.7 crore from ₹12 crore in Apr-Jun 2025.
Operating profit grew 2% to ₹0.96 crore, an operating margin of 1.9% (down 5.9 points from a year ago).
Net profit turned into a loss of ₹0.17 crore, from a profit of ₹1.2 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −10%, swings to a loss.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 49.7 | 12.0 | +313% |
| Operating profit (EBITDA) | 1.0 | 0.9 | +2% |
| Operating margin | 1.9% | 7.8% | −5.9 pts |
| Net profit | -0.2 | 1.2 | swings to a loss |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 13 Aug 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release
- 13 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 11 Aug 2026Statement Of Deviation Or Variation In The Use Of Proceeds Of Rights Issue For The Quarter Ended 30Th June, 2026.
- 11 Aug 2026Unaudited Standalone & Consolidated Financial Results Of The Company For The Quarter Ended 30Th June, 2026.
- 11 Aug 2026Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Held On Tuesday, 11Th August, 2026.
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.